Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.815 -0.515 (-7.03%)
Streaming Delayed Price Updated: 3:38 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
News headline image
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Cannabis Category Performances Last Week Ranged From +5.2% To -2.3% ↗
The 5 categories in the cannabis sector perform quite differently week to week and last week was no exception. This article is a summary of how each category performed last week, in descending order... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From November 25, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 23, 2022 ↗
 
Via Benzinga
News headline image
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes ↗
(Part one of a four-part series) 
Via Benzinga
News headline image
COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript ↗
CMPS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
Compass Pathways: Q3 Earnings Insights ↗
Compass Pathways (NASDAQ:CMPS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Psychedelics And Treatment-Resistant Depression: Companies Weigh In On The Important Issue ↗
(Part three of a four-part series) Have a look at previous stories: 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022 ↗
 
Via Benzinga
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022 ↗
 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Continued To Decline Last Week ↗
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS' Published Results ↗
(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022 ↗
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Clinical Stage Psychedelic Stock Index Up 6%; Therapy Clinic Stocks Down 8% ↗
We highlight the performance of our Psychedelic Drug Stocks Index and the 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of different psychedelic... 
Via Talk Markets
News headline image
A Comparison Of 5 Psychedelic ETFs And Indices ↗
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector. 
Via Talk Markets
News headline image
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 
Via Benzinga
News headline image
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 8, 2022 ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
News headline image
The Psychedelic Drug Stocks Index Continued To Plummet Last Week ↗
In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD. 
Via Talk Markets
News headline image
Compass Pathways, Allied Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
News headline image
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance ↗
(Part four of a four-part series) See previous stories in this series:  
Via Benzinga
News headline image
COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights ↗
Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 3, 2022 ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
News headline image
Psyched Wellness is The First Public Company To Bring Amanita Muscaria For Human Consumption To The U.S. ↗
Easily identified by its red cap covered with white dots and a white stem, the Amanita muscaria mushroom is probably the most famous and easily recognizable mushroom in the world. Popularized by Lewis... 
Via Benzinga
News headline image
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.